Filter News
Area of Research
- (-) National Security (2)
- (-) Nuclear Science and Technology (2)
- Biological Systems (1)
- Biology and Environment (16)
- Clean Energy (6)
- Computational Biology (2)
- Computational Engineering (1)
- Fusion and Fission (1)
- Isotopes (5)
- Materials (7)
- Materials for Computing (2)
- Neutron Science (11)
- Supercomputing (17)
News Type
News Topics
- (-) Biomedical (4)
- 3-D Printing/Advanced Manufacturing (27)
- Advanced Reactors (13)
- Artificial Intelligence (13)
- Big Data (6)
- Bioenergy (5)
- Biology (5)
- Biotechnology (1)
- Buildings (1)
- Chemical Sciences (2)
- Climate Change (5)
- Composites (3)
- Computer Science (22)
- Coronavirus (3)
- Cybersecurity (20)
- Decarbonization (3)
- Energy Storage (2)
- Environment (6)
- Exascale Computing (1)
- Frontier (1)
- Fusion (10)
- Grid (6)
- High-Performance Computing (4)
- Isotopes (5)
- Machine Learning (13)
- Materials (8)
- Materials Science (11)
- Molten Salt (4)
- Nanotechnology (1)
- National Security (34)
- Neutron Science (11)
- Nuclear Energy (41)
- Partnerships (4)
- Physics (3)
- Quantum Science (1)
- Security (11)
- Simulation (1)
- Space Exploration (6)
- Summit (2)
- Sustainable Energy (9)
- Transformational Challenge Reactor (4)
- Transportation (2)
Media Contacts
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
A team of researchers has developed a novel, machine learning–based technique to explore and identify relationships among medical concepts using electronic health record data across multiple healthcare providers.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.